Table 3. Echocardiographic data from Metrnβ−/− mice injected with AAV9-Metrnβ or AAV9-null after ISO-induced hypertrophy.
| CT | ISO | ||||
|---|---|---|---|---|---|
| AAV-null | AAV-Metrnβ | AAV-null | AAV-Metrnβ | P value | |
| IVSd (mm) | 0.59 ± 0.3 | 0.53 ± 0.3 | 0.87 ± 0.04*** | 0.76 ± 0.04** | ****, # |
| LVPWd (mm) | 0.64 ± 0.02 | 0.66 ± 0.04 | 0.85 ± 0.04** | 0.80 ± 0.04 | *** |
| LVIDd (mm) | 4.34 ± 0.3 | 4.26 ± 0.16 | 4.55 ± 0.08 | 4.30 ± 0.13 | |
| IVSs (mm) | 1.02 ± 0.04 | 0.80 ± 0.06# | 1.48 ± 0.07**** | 1.25 ± 0.02***,# | ****, ### |
| LVPWs (mm) | 0.76 ± 0.02 | 0.84 ± 0.05 | 1.11 ± 0.05*** | 1.15 ± 0.09** | **** |
| LVIDs (mm) | 3.23 ± 0.27 | 3.41 ± 0.17 | 3.24 ± 0.13 | 3.15 ± 0.19 | |
| EF (%) | 57.4 ± 2.7 | 47.2 ± 3.3 | 61.7 ± 3.3 | 59.0 ± 4.1 | * |
| FS (%) | 26.0 ± 1.7 | 20.4 ± 1.7 | 28.8 ± 2.1 | 27.0 ± 2.5 | * |
| EDV (mm3) | 87.5 ± 13.8 | 81.9 ± 7.2 | 95.1 ± 4.3 | 83.4 ± 6.1 | |
| ESV (mm3) | 43.9 ± 9.0 | 48.4 ± 5.8 | 42.8 ± 4.2 | 40.2 ± 5.5 | |
| Heart rate | 392.6 ± 27.1 | 292.6 ± 28.1## | 485.2 ± 8.8** | 453.4 ± 12.9**** | ****, ## |
| LVm (mg) | 108.6 ± 10.1 | 88.2 ± 5.3 | 164.3 ± 2.9** | 123.8 ± 16.3*,# | ***, ## |
| Aortic peak (m/s) | 1.08 ± 0.04 | 0.76 ± 0.07## | 1.21 ± 0.06 | 0.89 ± 0.05## | *, #### |
| VTI (cm) | 4.66 ± 0.27 | 4.08 ± 0.55 | 4.93 ± 0.44 | 3.60 ± 0.42 | # |
| E peak (m/s) | 0.78 ± 0.04 | 0.68 ± 0.05 | 0.88 ± 0.09 | 0.86 ± 0.07 | |
| Mitral deceleration (ms) | 27.0 ± 3.1 | 27.4 ± 1.5 | 25.2 ± 1.5 | 29.5 ± 1.9 | |
All measurements are expressed as mean ± SEM; n = 5 mice/group. Data were analyzed by two-way ANOVA, where *, P < 0.05, **, P < 0.001, ***, P < 0.0001, ****, P < 0.00001 for ISO effect; #, P < 0.05, ##, P < 0.001, ###, P < 0.0001, ####, P < 0.00001 for AAV9-Metrnβ effect. d, after diastole; EDV, end diastolic volume; s, after systole.